These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1901292)

  • 41. D-glucaric-acid excretion as a test for hepatic enzyme induction.
    Aarts EM
    Lancet; 1971 Apr; 1(7704):859. PubMed ID: 4102545
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical and experimental observations on metabolism of glucuronic acid].
    SUDHOF H
    Dtsch Arch Klin Med; 1954; 201(1):89-110. PubMed ID: 13173298
    [No Abstract]   [Full Text] [Related]  

  • 43. [Metabolism of rifampicin in the human body (2nd report)--Initial change of the rifampicin metabolism, its glucuronidation and its enzymatic oxidation in the stomach].
    Nakagawa H
    Kekkaku; 1987 Nov; 62(11):527-47. PubMed ID: 3444195
    [No Abstract]   [Full Text] [Related]  

  • 44. [Interrelation of organs centering around the liver].
    Sanbe K
    Nihon Naika Gakkai Zasshi; 1970 Dec; 59(13):Suppl:1-3. PubMed ID: 5534266
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of steroidal structure on glucuronoside formation by mouse liver and kidney.
    BERLINER DL; STEVENS W; DOUGHERTY TF
    Proc Soc Exp Biol Med; 1962 Jun; 110():268-70. PubMed ID: 13867934
    [No Abstract]   [Full Text] [Related]  

  • 46. Liver export proteins and trauma.
    Fleck A; Colley CM; Myers MA
    Br Med Bull; 1985 Jul; 41(3):265-73. PubMed ID: 3896382
    [No Abstract]   [Full Text] [Related]  

  • 47. Endocrine functioning and psychological disorders.
    Strain GW; Strain JJ
    Psychosom Med; 1978 Feb; 40(1):2-3. PubMed ID: 622428
    [No Abstract]   [Full Text] [Related]  

  • 48. Endocrine aspects of liver disease.
    Jenkins RM
    Br Med J; 1980 Feb; 280(6213):568-9. PubMed ID: 7370592
    [No Abstract]   [Full Text] [Related]  

  • 49. [Patient care in long-term illness (III). Nutritional implications in hepatic diseases].
    Kim MJ
    Taehan Kanho; 1988 Aug; 27(3):7-20. PubMed ID: 3139913
    [No Abstract]   [Full Text] [Related]  

  • 50. [RESEARCH ON GLUCURONO- CONJUGATION IN NORMAL SUBJECTS AND IN CHRONIC LIVER DISEASES].
    MARCUS N; GHEORGHIU T; VLADESCU C
    Stud Cercet Med Interna; 1963; 38():525-8. PubMed ID: 14059803
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacokinetics in liver disease.
    Davey PG
    J Antimicrob Chemother; 1988 Jan; 21(1):1-5. PubMed ID: 3281925
    [No Abstract]   [Full Text] [Related]  

  • 52. The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers.
    Dunn A; Takebe N; Chen A; Kummar S; Piekarz R; Kiesel B; Moore N; Doroshow J; Beumer JH; Gobburu JVS
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):157-167. PubMed ID: 38483557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic Impairment as a Risk Factor for Drug Safety: Suitability and Comparison of Four Liver Scores as Screening Tools.
    Golla K; Benesic A; Mannell H; Dreischulte T; Grill E; Strobach D
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
    El-Khateeb E; Achour B; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
    Mol Pharm; 2021 Sep; 18(9):3563-3577. PubMed ID: 34428046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sources of Interindividual Variability.
    Lin YS; Thummel KE; Thompson BD; Totah RA; Cho CW
    Methods Mol Biol; 2021; 2342():481-550. PubMed ID: 34272705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endoscopic Sedation of the Patient With Cirrhosis.
    Edelson JC; Rockey DC
    Clin Liver Dis (Hoboken); 2018 Dec; 12(6):165-169. PubMed ID: 30988936
    [No Abstract]   [Full Text] [Related]  

  • 57. Might hyperbaric oxygen therapy (HBOT) reduce renal injury in diabetic people with diabetes mellitus? From preclinical models to human metabolomics.
    Harrison LE; Giardina C; Hightower LE; Anderson C; Perdrizet GA
    Cell Stress Chaperones; 2018 Nov; 23(6):1143-1152. PubMed ID: 30374882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls.
    Song IH; Borland J; Savina PM; Chen S; Patel P; Wajima T; Peppercorn AF; Piscitelli SC
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):342-348. PubMed ID: 26097786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
    Hirano M; Meyers D; Golla G; Pal P; Pinot P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
    Clin Pharmacokinet; 2015 Jul; 54(7):761-70. PubMed ID: 25633714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations.
    Imani F; Motavaf M; Safari S; Alavian SM
    Hepat Mon; 2014 Oct; 14(10):e23539. PubMed ID: 25477978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.